Error
Sorry, the page you're looking for has moved or doesn't exist.
You can access content using the navigation or using the search function.
Articles and blogs
|
June 13, 2023 · Medicare Insights Team
On June 6, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important changes. Read more... |
|
May 22, 2023 · Public Policy & Regulatory Affairs Team
In Episode #20, the Policy Guys visit with Andrew Sabolic, former Deputy Director at Florida’s Division of Workers’ Compensation and current Executive Director at WCI for an in-depth discussion about the workers’ comp regulations – how they are formulated, refined and written into law, as well as useful tips on how best to work with state regulators. Read more... |
|
|
May 19, 2023 · Medicare Insights Team
The Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, version 3.9, dated 5/15/2023, which includes two significant changes. Read more... |
|
|
May 18, 2023 · Medicare Insights Team
On April 27, 2023, CMS released the NGHP Applicable Plan Appeals Reference Guide as a way to streamline the appeal process, which includes types of appeals and documentation needed to support appeals. Read more... |
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
|
May 01, 2023 · Optum Workers' Comp and Auto No-Fault
Cost savings programs can help insurers cut premium costs and attract clients in the notoriously difficult auto insurance line. Read more... |
|
|
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more... |
|
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
Page 4 of 15